New scalp injection trial aims to regrow hair in alopecia areata

NCT ID NCT06826196

Summary

This is an early-stage study to see if a new injectable solution called ALD-102 is safe and can help regrow hair in people with alopecia areata. Researchers will give small injections into the scalp every four weeks for two months and compare the results to untreated or placebo-treated spots. The study will enroll 24 adults to check for side effects and see if the treatment shows any early signs of helping hair grow back.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALOPECIA AREATA (AA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Centre de Recherche Saint-Louis

    RECRUITING

    Québec, Quebec, QC G1W 4R4, Canada

  • Clinical Trial Research Institute

    RECRUITING

    Thousand Oaks, California, 91320, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Dermatology Specialists of Spokane

    RECRUITING

    Spokane, Washington, 99202, United States

  • Innovaderm

    RECRUITING

    Montreal, Quebec, H2X 2V1, Canada

  • Options Research Group

    RECRUITING

    West Lafayette, Indiana, 47906, United States

  • The Brigham and Women's Hospital

    RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Centre for Clinical Trials

    RECRUITING

    Oakville, Ontario, L6J 7W5, Canada

Conditions

Explore the condition pages connected to this study.